Chemotherapeutic agents and the skin: An update

被引:153
作者
Heidary, Noushin [2 ]
Naik, Haley [3 ]
Burgin, Susan [1 ]
机构
[1] Beth Israel Deaconess Med Ctr, Dept Dermatol, Boston, MA 02215 USA
[2] NYU, Ronald O Perelman Dept Dermatol, New York, NY USA
[3] Stanford Univ, Med Ctr, Dept Med, Stanford, CA 94305 USA
关键词
D O I
10.1016/j.jaad.2008.01.001
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Chemotherapeutic agents give rise to numerous well described adverse effects that may affect the skin, hair, mucous membranes, or nails. The mucocutaneous effects of longstanding agents have been extensively studied and reviewed. Over the last 2 decades, a number of new molecular entities for the treatment of cancer have been approved by the United States Food and Drug Administration (FDA). This article reviews the cutaneous toxicity patterns of these agents. It also reviews one drug that has not received FDA approval but is in use Outside the United States and is important dermatologically. Particular emphasis is placed on the novel signal transduction inhibitors as well as on newer literature pertaining to previously described reactions.
引用
收藏
页码:545 / 570
页数:26
相关论文
共 306 条
  • [1] Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: A single-institution experience
    Abushullaih, S
    Saad, ED
    Munsell, M
    Hoff, PM
    [J]. CANCER INVESTIGATION, 2002, 20 (01) : 3 - 10
  • [2] Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors
    Adjei, AA
    Erlichman, C
    Sloan, JA
    Reid, JM
    Pitot, HC
    Goldberg, RM
    Peethambaram, P
    Atherton, P
    Hanson, LJ
    Alberts, SR
    Jett, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (08) : 1748 - 1757
  • [3] Dermatologic side effects associated with the epidermal growth factor receptor inhibitors
    Agero, Anna Liza C.
    Dusza, Stephen W.
    Benvenuto-Andrade, Cristiane
    Busam, Klaus J.
    Myskowski, Patricia
    Halpern, Allan C.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 55 (04) : 657 - 670
  • [4] Anhalt G J, 1997, Adv Dermatol, V12, P77
  • [5] Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta
    Apperley, JF
    Gardembas, M
    Melo, JV
    Russell-Jones, R
    Bain, BJ
    Baxter, J
    Chase, A
    Chessells, JM
    Colombat, M
    Dearden, CE
    Dimitrijevic, S
    Mahon, FX
    Marin, D
    Nikolova, Z
    Olavarria, E
    Silberman, S
    Schultheis, B
    Cross, NCP
    Goldman, JM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (07) : 481 - 487
  • [6] DIAGNOSTIC FEATURES OF TRANSFUSION-ASSOCIATED GRAFT-VERSUS-HOST DISEASE
    APPLETON, AL
    SVILAND, L
    PEARSON, ADJ
    WILKES, J
    GREEN, MA
    MALCOLM, AJ
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 1994, 47 (06) : 541 - 546
  • [7] Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate
    Arora, B
    Kumar, L
    Sharma, A
    Wadhwa, J
    Kochupillai, V
    [J]. ANNALS OF ONCOLOGY, 2004, 15 (02) : 358 - 359
  • [8] Docetaxel (Taxotere) extravasation: A report of five cases with treatment recommendations
    Ascherman, JA
    Knowles, SL
    Attkiss, K
    [J]. ANNALS OF PLASTIC SURGERY, 2000, 45 (04) : 438 - 441
  • [9] Panniculitis during dasatinib therapy for imatinib-resistant chronic myelogenous leukemia
    Assouline, Sarit
    Laneuville, Pierre
    Gambacorti-Passerini, Carlo
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (24) : 2623 - 2624
  • [10] Imatinib-induced sweet syndrome in a patient with chronic myeloid leukemia
    Ayirookuzhi, SJ
    Ramshesh, P
    Mills, G
    [J]. ARCHIVES OF DERMATOLOGY, 2005, 141 (03) : 368 - 370